Skip to main content

Advertisement

SpringerLink
Log in

Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Immune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolumab retreatment remains unresolved. In this retrospective study, in a cohort of 23 adult patients with r/r cHL who discontinued nivolumab in complete response (CR), the possibility of durable remission achievement (2-year PFS was 55.1%) was demonstrated. Retreatment with nivolumab has demonstrated efficacy with high overall response rate (ORR) and CR (67% and 33.3% respectively). At the final analysis, all patients were alive with median PFS of 16.5 months. Grade 3–4 adverse events (AEs) were reported in 36% of patients, and there was no deterioration in terms of nivolumab retreatment–associated complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data Availability

Not applicable

References

  1. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM (2018) Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428–1439. https://doi.org/10.1200/JCO.2017.76.0793

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH, for the KEYNOTE-087 (2017) KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125–2132. https://doi.org/10.1200/JCO.2016.72.1316

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gauci M, Lanoy E, Champiat S, Caramella C et al (2019) Long-term survival in patients responding to anti-PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation. Clinical Cancer Research 25(3):946–956. https://doi.org/10.1158/1078-0432.ccr-18-0793

    Article  PubMed  Google Scholar 

  4. Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S (2018) Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer 18:946. https://doi.org/10.1186/s12885-018-4819-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B (2019) Discontinuation of anti-PD-antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology 30(7):1154–1161. https://doi.org/10.1093/annonc/mdz110

    Article  CAS  PubMed  Google Scholar 

  6. Myint ZW, Arays R, Raajasekar AKA, Wang P (2018) Long-term outcomes in patients after discontinuation of immune checkpoint inhibitors. J Clin Res Med 1(3):1–4. https://doi.org/10.1200/JCO.2018.36.15_suppl.e15086

    Article  Google Scholar 

  7. Atkinson VG, Ladwa R (2016) Complete responders to anti-PD1 antibodies. What happens when we stop? Ann Oncol 27(6):1116P. https://doi.org/10.1093/annonc/mdw379.11

  8. Myint Z, Arays R, Raajasekar AKA, Huang B, Chen Q, Wang P (2018) Long-term outcomes in patients after discontinuation of PD1/PDL1 inhibitors. J Clin Oncol 36:e15086. https://doi.org/10.1200/JCO.2018.36.15_suppl.e15086

    Article  Google Scholar 

  9. Spigel DR, et al (2017) CHECKMATE153: Randomized results of continuous vs 1-year fixed-duration nivolumab in patients with advanced non-small cell lung cancer. Ann Oncol 28:5. Abstract 1297O. https://www.primeoncology.org/app/uploads/prime_activities/42584/VPS_Madrid_1297O_Lung_Spigel.pdf

  10. Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano JM, Ghesquieres H, Dercle L, Houot R, Lymphoma Study Association (2018) Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood 131:2856–2859. https://doi.org/10.1182/blood-2018-03-841262

    Article  CAS  PubMed  Google Scholar 

  11. Lepik K, Fedorova L, Mikhailova N et al (2019) Cessation of immune checkpoint inhibitors therapy in r/r Hodgkin lymphoma: should we consider HSCT? 45th Annual Meeting of the European Society for Blood and Marrow Transplantation, Abstract collection. Poster number A232

  12. Goodman A (2017) Retreatment with checkpoint inhibitors may be feasible for some patients with NSCLC. The ASCO post. https://www.ascopost.com/issues/july-10-2017/retreatment-with-checkpoint-inhibitors-may-be-feasible-for-some-patients-with-nsclc. Accessed 10 June 2017

  13. Santini FC, Rizvi H, Wilkins O, van Voorthuysen M, Panora E, Halpenny D, Kris MG, Rudin CM, Chaft JE, Hellmann MD (2017) Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol 35(15):9012. https://doi.org/10.1200/JCO.2017.35.15_suppl.9012

    Article  Google Scholar 

  14. Fujita K, Uchida N, Yamamoto Y, et al (2019) Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Research 39(7):3917–3921. 10.21873/anticanres.13543

  15. Alaiwi SA, Martini DJ, Xie W et al (2019) Safety and efficacy of restarting immune checkpoint inhibitors (ICI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 37(7):652–652. https://doi.org/10.1200/JCO.2019.37.7_suppl.652

    Article  Google Scholar 

  16. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29:250–255. https://doi.org/10.1093/annonc/mdx642

    Article  CAS  PubMed  Google Scholar 

  17. Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD (2014) Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 25:2277–2284. https://doi.org/10.1093/annonc/mdu441

    Article  PubMed  PubMed Central  Google Scholar 

  18. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, de Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglino P, Carnevale Schianca F, Mandalà M, di Guardo L, del Vecchio M (2014) Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 110:1721–1726. https://doi.org/10.1038/bjc.2014.126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S, MDX010-20 investigators (2013) Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 19:2232–2239. https://doi.org/10.1158/1078-0432.CCR-12-3080

    Article  CAS  PubMed  Google Scholar 

  20. Maiko N, Nakaya A, Kurata T, et al (2018) Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget 9(64):32298–32304. 10.18632/oncotarget.25949

  21. Pellegrini C, Casadei B, Cellini C, Argnani L, Cavo M, Zinzani PL (2018) Sequential double bridging to transplant with diversified anti-PD1 monoclonal antibodies retreatment in relapsed Hodgkin lymphoma: a case report. J Cancer Sci Ther 10(6):149. https://doi.org/10.4172/1948-5956.1000534

    Article  Google Scholar 

  22. Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 134:1144–1153. https://doi.org/10.1182/blood.2019000324

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Lepik KV, Mikhailova NB, Moiseev IS, et al (2019) Nivolumab for the treatment of relapsed and refractory classical Hodgkin lymphoma after ASCT and in ASCT­naïve patients. Leukemia & Lymphoma 1–4. https://doi.org/10.1080/10428194.2019.1573368

  24. Kozlov AV, Kazantzev IV, Iukhta TV, et al (2019) Nivolumab in pediatric Hodgkin’s lymphoma. CTT. 10.18620/ctt-1866-8836-2019-8-4-41-48

  25. Lepik KV, Fedorova LV, Kondakova EV et al (2020) A phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed/refractory Hodgkin lymphoma. Hemasphere 4(5):480. 2020 https://doi.org/10.1097/HS9.0000000000000480

  26. Shi Y, Su H, Song Y, Jiang W, Sun X, Qian W, Zhang W, Gao Y, Jin Z, Zhou J, Jin C, Zou L, Qiu L, Li W, Yang J, Hou M, Zeng S, Zhang Q, Hu J, Zhou H, Xiong Y, Liu P (2019) Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (Orient-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol 6:e12–e19. https://doi.org/10.1016/S2352-3026(18)30192-3

    Article  PubMed  Google Scholar 

  27. Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Yang Y, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J (2018) Tislelizumab (Bgb-A317) for relapsed/refractory classical Hodgkin lymphoma: preliminary efficacy and safety results from a phase 2 study. Blood 132:682. https://doi.org/10.1182/blood-2018-99-117848

    Article  Google Scholar 

  28. Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W (2019) Addition of low-dose decitabine to anti-Pd-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 37:1479–1489. https://doi.org/10.1200/JCO.18.02151

    Article  CAS  PubMed  Google Scholar 

  29. Chen R, Gibb AL, Collins GP, Popat R, el-Sharkawi D, Burton C, Lewis D, Miall FM, Forgie A, Compagnoni A, Andreola G, Brar S, Thall A, Woolfson A, Radford J (2017) Blockade of the PD-1 checkpoint with anti–PD-L1 antibody Avelumab is sufficient for clinical activity in relapsed/refractory classical Hodgkin lymphoma (cHL). Hematol Oncol 35:67. https://doi.org/10.1002/hon.2437_54

    Article  Google Scholar 

  30. Hamadani M, Collins GP, Samaniego F, Spira AI, Davies A, Radford J, Caimi P, Menne T, Boni J, Cruz H, Feingold J, He S, Wuerthner J, Horwitz SM (2018) Phase 1 study of Adct-301 (Camidanlumab Tesirine), a novel pyrrolobenzodiazepine-based antibody drug conjugate, in relapsed/refractory classical Hodgkin lymphoma. Blood 132:928. https://doi.org/10.1182/blood-2018-99-118198

    Article  Google Scholar 

  31. Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, Ravic M, Knackmuss S, Marschner JP, Pogge von Strandmann E, Borchmann P, Engert A (2015) A phase 1 study of the bispecific anti-CD30/CD16A antibody construct Afm13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 125:4024–4031. https://doi.org/10.1182/blood-2014-12-614636

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Smith SM, Schöder H, Johnson JL, et al (2013) The Anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: cancer and leukemia group B 50602 (Alliance) Leukemia & Lymphoma 54:1405–1410. 10.3109/10428194.2012.744453

  33. Freedman AS, Kuruvilla J, Assouline SE et al (2010) Clinical activity of lucatumumab (Hcd122) in patients (Pts) with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592). Blood 116:284. https://doi.org/10.1182/blood.V116.21.284.284

    Article  Google Scholar 

  34. Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Fedorova LV, Tsvetkova LA, Kotselyabina PV, Borzenkova ES, Babenko EV, Popova MO, Darskaya EI, Baykov VV, Moiseev IS, Afanasyev BV (2020) A study of safety and efficacy of nivolumab and bendamustine (NB) in patients with relapsed/refractory Hodgkin lymphoma after nivolumab monotherapy failure. HemaSphere 4:e401. https://doi.org/10.1097/HS9.0000000000000401

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Alexander Kulagin, Ilya Kazantzev, and Vladislav Evseev for assistance with manuscript preparation.

Author information

Authors and Affiliations

  1. RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation

    Liudmila V. Fedorova, Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Vadim V. Baykov, Elena V. Babenko, Andrey V. Kozlov, Ivan S. Moiseev & Boris V. Afanasyev

Authors
  1. Liudmila V. Fedorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kirill V. Lepik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalia B. Mikhailova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena V. Kondakova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuri R. Zalyalov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vadim V. Baykov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elena V. Babenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrey V. Kozlov
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ivan S. Moiseev
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Boris V. Afanasyev
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: Fedorova LV, Lepik KV, Mikhailova NB, Moiseev IS, Afanasyev BV

Provision of study materials or patients: Fedorova LV, Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Kozlov AV, Babenko EV, Baykov VV

Collection and assembly of data: Fedorova LV, Lepik KV, Mikhailova NB, Kondakova EV, Zalyalov YR, Kozlov AV

Data analysis and interpretation: Fedorova LV, Lepik KV, Mikhailova NB, Kondakova EV, Moiseev IS, Afanasyev BV.

Manuscript writing: Fedorova LV, Lepik KV, Mikhailova NB

Final approval of manuscript: all authors

Accountable for all aspects of the work: Fedorova LV, Lepik KV, Mikhailova NB

Corresponding author

Correspondence to Liudmila V. Fedorova.

Ethics declarations

Ethics approval and consent to participate

This study was performed in accordance with the 1964 Helsinki declaration and approved by the institutional review board. All enrolled patients gave written informed consent.

Consent for publication

Not applicable

Conflict of interest

The authors declare no competing interests.

Code availability

Not applicable

Materials availability

Not applicable

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(PPTX 14167 kb)

ESM 2

(PPTX 14222 kb)

ESM 3

(PPTX 14485 kb)

ESM 4

(PPTX 15138 kb)

ESM 5

(DOCX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fedorova, L.V., Lepik, K.V., Mikhailova, N.B. et al. Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma. Ann Hematol 100, 691–698 (2021). https://doi.org/10.1007/s00277-021-04429-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04429-8

Keywords

Search

Navigation